US › Healthcare

Foghorn Therapeutics Inc (FHTX)

US · Healthcare · Biotechnology

$1.85-2.12%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$16.1M

Revenue YoY

+112.7%

Net profit

$-7.2M

EPS

$-0.10

EPS estimate

$-0.23

Net margin

-44.7%

EPS came in at -0.10 against a street estimate of -0.23 — a beat of 56.5%.

Key statistics

Market cap

$115.8M

Forward P/E

0.0

P/B

2,005.35

Book value

$-1.38

EPS (TTM)

$-1.01

52-week high

$7.61

52-week low

$1.79

50-day MA

$4.76

200-day MA

$4.95

Beta

3.01

Analyst view

Analysts rate Foghorn Therapeutics Inc a buy (6 buy, 4 hold, 0 sell out of 10) with an average price target of $6.00.

Shareholding

Insiders

14.13%

Institutions

81.62%

Largest institutional holders

Fund	Stake
Flagship Ventures Management, Inc.	21.34%
Bvf Inc	9.84%
FMR Inc	9.61%
Deerfield Management Co	7.40%
BlackRock Inc	4.42%
Euclidean Capital LLC	2.65%
Vanguard Capital Management, LLC	2.52%
Geode Capital Management, LLC	1.53%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Foghorn Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.